⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12064988 | 0.78 | — | — | |
| SCHEMBL1491225 | 0.78 | — | — | |
| SCHEMBL20241869 | 0.76 | — | — | |
| SCHEMBL17177047 | 0.76 | — | — | |
| SCHEMBL19301873 | 0.76 | — | — | |
| SCHEMBL24741443 | 0.75 | — | — | |
| SCHEMBL5184661 | 0.75 | — | — | |
| SCHEMBL18658857 | 0.75 | — | — | |
| SCHEMBL14908536 | 0.73 | — | — | |
| SCHEMBL13464191 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| CN-110337294-B | Pyrrolopyrimidines as CFTR potentiators | 囊性纤维化基金会 | 2022-11-01 | — | — | CN | disclosed |
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20210171534-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION | 2021-06-10 | — | — | US | disclosed |
| US-20200017512-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | PFIZER INC. | 2020-01-16 | — | — | US | disclosed |
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| US-10301315-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180141954-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| WO-2017045751-A1 | COMPOUNDS AS ASIC INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| CN-102665718-B | Heterocyclic compounds useful as PDK1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-03-09 | — | — | CN | disclosed |
| CN-104203948-A | 1H-pyrrolo [2,3-b ] pyridine derivatives and their use as kinase inhibitors | VERNALIS R&D LTD | 2014-12-10 | — | — | CN | disclosed |
| CN-103313978-A | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | disclosed |
| US-20120083835-A1 | STAPLE CARTRIDGE COMPRISING A TISSUE THICKNESS COMPENSATOR | ETHICON ENDO-SURGERY, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| CN-101353338-B | Osamine modified water-soluble coumarin ketone derivates and preparation thereof | UNIV SHANGHAI JIAOTONG | 2011-05-04 | — | — | CN | disclosed |
| CN-101353338-A | Osamine modified water-soluble coumarin ketone derivates and preparation thereof | UNIV SHANGHAI JIAOTONG (CN) | 2009-01-28 | — | — | CN | disclosed |